TITLE:
Influenza A virus-induced expression of a GalNAc transferase, GALNT3, via miRNAs is required for enhanced viral replication (Dissertation_全文)

AUTHOR(S):
Nakamura, Shoko

CITATION:
Nakamura, Shoko. Influenza A virus-induced expression of a GalNAc transferase, GALNT3, via miRNAs is required for enhanced viral replication. 京都大学, 2016, 博士(医科学)

ISSUE DATE:
2016-03-23

URL:
https://doi.org/10.14989/doctor.k19633

RIGHT:
Influenza A virus-induced expression of a GalNAc transferase, GALNT3, via miRNAs is required for enhanced viral replication

Shoko Nakamura\textsuperscript{1,2}, Masayuki Horie\textsuperscript{1,*}, Tomo Daidoji\textsuperscript{3}, Tomoyuki Honda\textsuperscript{1}, Mayo Yasugi\textsuperscript{2}, Atsushi Kuno\textsuperscript{3}, Toshihisa Komori\textsuperscript{3}, Daisuke Okuzaki\textsuperscript{3}, Hisashi Narimatsu\textsuperscript{4}, Takaaki Nakaya\textsuperscript{4} and Keizo Tomonaga\textsuperscript{1,2,8,9}

\textsuperscript{1}Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto, Japan.
\textsuperscript{2}Department of Tumor Viruses, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
\textsuperscript{3}Department of Infectious Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan.
\textsuperscript{4}Laboratory of Veterinary Public Health, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
\textsuperscript{5}Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan.
\textsuperscript{6}Department of Cell Biology, Unit of Basic Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
\textsuperscript{7}DNA-chip Development Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
\textsuperscript{8}Department of Mammalian Regulatory Network, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.

Running Title: Influenza A virus induces GALNT3 expression via miRNAs

\textsuperscript{*}Present address; Transboundary Animal Diseases Research Center, Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan.
\textsuperscript{9}To whom correspondence should be addressed. Department of Viral Oncology, Institute for Virus Research, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Tel: +81-75-751-3997, Fax: +81-75-751-4000, E-mail: tomonaga@virus.kyoto-u.ac.jp

Abstract word count: 245; Text word count: 6950
Abstract

Influenza A virus (IAV) affects the upper and lower respiratory tracts and rapidly induces the expression of mucins, which are common O-glycosylated proteins, on the epithelial surfaces of the respiratory tract. Although mucin production is associated with the inhibition of virus transmission as well as characteristic clinical symptoms, little is known regarding how mucins are produced on the surfaces of respiratory epithelial cells and how they affect IAV replication. In this study we found that two miRNAs, miR-17-3p and miR-221, which target GalNAc transferase 3 (GALNT3) mRNA, are rapidly downregulated in human alveolar basal epithelial cells during the early stage of IAV expression. We demonstrated that the expression of GALNT3 mRNA is upregulated in an IAV replication-dependent fashion and leads to mucin production in bronchial epithelial cells. A lectin microarray analysis revealed that the stable expression of GALNT3 by human alveolar basal epithelial cells induces mucin-type O-glycosylation modifications similar to those present in IAV-infected cells, suggesting that GALNT3 promotes mucin-type O-linked glycosylation in IAV-infected cells. Notably, analyses using siRNAs and miRNA mimics showed that GALNT3 knockdown significantly reduces IAV replication. Furthermore, IAV replication was markedly decreased in embryonic fibroblast cells obtained from galnt3-knockout mice. Interestingly, IAV-infected galnt3-knockout mice exhibited high mortality and severe pathological alterations in the lungs compared to wild type mice. Our results demonstrate not only the molecular mechanism underlying rapid mucin production during IAV infection, but also the contribution of O-linked glycosylation to the replication and propagation of IAV in lung cells.
Importance

Viral infections that affect the upper or lower respiratory tracts, such as Influenza A virus (IAV), rapidly induce mucin production on the epithelial surfaces of respiratory cells. However, the details of how mucin-type O-linked glycosylation is initiated by IAV infection and how mucin production affects viral replication have not yet been elucidated. In this study, we show that two miRNAs that target the UDP-GalNAc transferase GALNT3 are markedly decreased during the early stage of IAV infection, resulting in the upregulation of GALNT3 mRNA. We also demonstrate that the expression of GALNT3 initiates mucin production and affects IAV replication in infected cells. This is the first report demonstrating the mechanism underlying the miRNA-mediated initiation of mucin-type O-glycosylation in IAV-infected cells and its role in viral replication. Our results have broad implications for understanding IAV replication and suggest a strategy for the development of novel anti-influenza approaches.
Introduction

Mucin-type O-linked glycosylation is a fundamental form of glycosylation that occurs in the Golgi apparatus in eukaryotes. This type of glycosylation is initiated by the UDP-GalNAc polypeptide:N-acetylgalactosaminyltransferase (ppGalNAcT) family and formed by GalNAc attachment to the serine/threonine (Ser/Thr) side chains of protein substrates (1-3). The generation of complex O-linked glycans is involved in a variety of biological molecular processes, such as cell motility, cell growth and death, cell-to-cell communication, the immune response, and host-pathogen interactions (4-6). On the other hand, abnormalities in O-linked glycan modifications have been shown to be linked to a variety of diseases, including cancers (7).

O-linked glycosylation has also been shown to be involved in the various steps of viral infection. For some viruses, glycosylation of the cell surface play a critical role in determining infectivity and transmissibility (8, 9). Furthermore, it has been reported that mutations and/or selection in the glycosylation sites of viral envelope glycoproteins during infection is a critical step to escape from the host immune system (10). These observations suggest that the patterns of the O-linked glycosylation of both the viral and host proteins could be a key factor to influence viral virulence, in turn contributing to viral pathogenesis.

The most abundant and well-characterized O-glycosylation occurs on mucins, which are large cell-surface-bound and secreted glycoproteins. In viral infections affecting the upper or lower respiratory tracts, such as influenza viruses and respiratory syncytial virus (RSV), the increased production of mucus, which is largely composed of mucins, is commonly induced in the epithelial surfaces of the respiratory tract (11, 12). Recent studies have revealed that mucins are upregulated in epithelial cells soon after
the infection by respiratory viruses, such as Influenza A virus (IAV) both in vivo and in
vitro. Moreover, mucin production in the respiratory tract during the early stage of viral
infections is associated with characteristic clinical symptoms as well as viral elimination
(12, 13). It has also been shown that the expression of MUC5B, which is the most
abundant mucin in the airway epithelium in humans, is essential for mucociliary
clearance and airway defense against microbial infections in mice (14). However, the
details of how mucin expression is regulated during infection and how mucin
production affect viral replication have not yet been fully elucidated.

In this study, we attempted to understand the early host cell response to IAV
infection and its impact on IAV replication. Here, we show by microRNA (miRNA)
microarray analysis that the expression of two miRNAs, miR-17-3p and miR-221,
which target an UDP-GalNAc transferase, ppGalNAcT-3 (GALNT3), significantly
decreases as early as 4.5 h post-infection with IAV, resulting in the upregulation of
GALNT3 mRNA. The expression of GALNT3 was shown to be correlated with mucin
production and O-linked glycosylation modification in human alveolar basal epithelial
cells. Furthermore, we found that GALNT3 knockdown moderately but significantly
reduced IAV replication. Notably, IAV replication was shown to be markedly decreased
in mouse embryo fibroblast (MEF) cells obtained from galnt3-knockout (KO) mice. On
the other hand, galnt3-KO mice exhibited severe pathological alterations in the lungs by
the infection of IAV. Based on these results, we suggest that IAV infection induces the
expression of an UDP-GalNAc transferase and mucin-type O-linked glycosylation
modification via the miRNA machinery and also that GALNT 3 plays a dual function in
IAV infection; enhancement of IAV replication and control of viral propagation in vivo.
Materials and Methods

Cells and viruses. A549, BEAS-2B (American Type Culture Collection, CRL-9609), MDCK, and HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS). BEAS-2B cells stably expressing GALNT3 were generated as previously described (15). Briefly, an expression plasmid containing human GALNT3, pEF-hGALNT3, was transfected into BEAS-2B cells, and cell clones stably expressing GALNT3 were selected using 200 μg/ml Zeocin (Invitrogen) and cultured in DMEM containing 10% FCS. HEK293T cells were transfected with the constructed plasmids using Lipofectamine2000 (Invitrogen). A549, BEAS-2B, and HEK293T cells were infected with several IAV strains, including A/Puerto Rico/8/1934 (PR8 [H1N1]), A/WSN/1933 (WSN [H1N1]), A/Beijing/262/95 (Beijing [H1N1]), A/Suita/82/2011 (Suita [H3N2]) and A/Panama/2007/99 (Panama [H3N2]). UV-PR8 was generated by ultraviolet irradiation of PR8 for 15 min.

Plasmids. The human GALNT3 expression plasmid, pEF4-GALNT3, was used as reported previously (15). The Renilla luciferase reporter plasmid, pRL-tk-GALNT3-3’ UTR, which contains the 3’ untranslated region (3’ UTR) of GALNT3 mRNA, was generated by inserting the 3’ UTR of GALNT3 using the In-fusion cloning system. The mutants of the miR-221 and miR-17-3p binding regions, pRL-tk-GALNT3-3’ UTR 221 mut and 17-3p mut, were generated from the wild-type plasmid using PCR-based mutagenesis. We determined the binding sites for miR-221 and miR-17-3p by using microRNA.org and GENETYX ver.10 software. The pPolI vector and pPolI-CAT-WSN, pCAGGS-PA, pCAGGS-PB1, pCAGGS-PB2 and pCAGGS-NP plasmids were used as
miRNA microarray analysis. miRNA microarray analysis was carried out using an Agilent human miRNA microarray (V3) containing 20-40 features targeting each of 866 human miRNAs and 89 viral miRNAs cataloged in the Sanger database version 12.0 (design ID 021827). The total RNA was extracted from infected cells at 0.5, 1.5, or 4.5 h post-infection using miRNeasy (Qiagen) and subjected to microarray analysis in duplicate. As a control, we used the total RNA extracted from uninfected A549 cells at one time point of 0.5 h. One hundred nanograms of aliquots of total RNA were used to make the miRNA probes as previously described (16). The microarray data were deposited in the NCBI GEO database [GSE: 57508]. To identify significantly up- and downregulated miRNAs in the infected cells at 0.5, 1.5, or 4.5 h post-infection, one-way ANOVA (GeneSpring GX) with Tukey’s HSD post-hoc test was conducted to compare the differentially expressed miRNAs between IAV-infected and control cells ($P < 0.05$).

Titration of infectious units. To determine viral titers, monolayers of MDCK cells in 96-well plates were infected with the trypsin-pretreated supernatants of IAV-infected cells for 1 h at 37°C, washed 3 times with PBS, changed to DMEM/F12 containing 0.2% BSA and then incubated for 12 h at 37°C. At 12 h post-infection, the cells were washed 3 times with PBS and fixed with 100% ethanol for 3 min. Virus samples were pre-treated with 1.0 µg/ml of acetylated-trypsin for 1 h at 37°C. The viral titers were obtained using a focus forming assay as previously described.

Immunofluorescence assay. PR8-infected MDCK cells in 96-well plates were fixed
with 100% ethanol, incubated with anti-NP antibody (C43; 1/1,000 dilution) for 1 h at 37°C, washed 4 times with PBS, and reacted with Alexa Fluor 488 anti-mouse antibody (1/1,000 dilution) for 45 min at 37°C. After washing 4 times in PBS, the plates were coated in PBS containing 50% glycerol. To analyze the cell tropism of the WSN strain, differentiated HBECs, which are described in the three-dimensional cell culture subsection below, were infected with WSN for 9 h (multiplicity of infection [MOI] = 3.0), fixed with 4% paraformaldehyde for 15 min, and reacted with 0.4% Triton X-100 for 5 min. The fixed HBECs were transferred to glass slides and incubated with anti-MUC5AC (ab78660; 1/200 dilution) and anti-NP (C43; 1/500 dilution) for 1 h at 37°C. After washing 3 times in PBS, the cells were incubated with Alexa Fluor 488 anti-rabbit and Alexa Fluor 555 anti-mouse antibodies (1/1,000 dilution) for 45 min at 37°C.

**Taqman microRNA assay.** The Taqman MicroRNA Reverse Transcription kit (Life technologies) was used for the reverse transcriptase reaction in a 15 µl mixture containing 10 ng RNA, 0.15 µl dNTPs (100 mmol/l), 1 µl MultiScribe RTase, 1.5 µl 10× RT buffer, 0.19 µl RNase inhibitor, 4.16 µl RNase-free water, and 3 µl RT primers. The reaction conditions were as follows: 16°C for 30 min, 42°C for 30 min, and 85°C for 5 min. Real-time qPCR was carried out in a 20 µl mixture containing 10 µl Taqman 2× Universal Master Mix (ABI), 1 µl 20× Taqman microRNA mix, 7.67 µl distilled water, and 1.33 µl RT reaction product. The reaction conditions were 95°C for 10 min, followed by 40 cycles of amplification (95°C for 15 sec, 60°C for 60 sec).
**Transfection of miRNA mimics and siRNA.** After the harvested HEK293T cells were incubated in 12-well plates for 24 h at 37°C, 5 nmol/l of miR-221 mimic, miR-17-3p mimic, or scrambled small RNA (si control) were transfected using HiPerfect reagent (Qiagen) at a concentration of 6 µl/ml. At 48 h post-transfection, total RNA was isolated using TRIzol reagent (Invitrogen). BEAS-2B cells were seeded in 12-well plates and incubated for 48 h at 37°C. Then, 5 nmol/l of siRNA against GALNT3 and GALNT1 (siGALNT3, siGALNT1), miR-221 mimic, miR-17-3p mimic and si control were transfected into the cells using HiPerfect Reagent.

**Dual-luciferase reporter assay.** The harvested HEK293T cells were transfected with pRL-tk-GALNT3-3' UTR, pRL-tk-GALNT3-3' UTR-221 mut and 17-3p mut plasmids using Lipofectamine2000 in 24-well plates. At 24 h post-transfection, the cell lysates were collected using a Dual-luciferase Reporter Assay Kit (Promega). We measured the luciferase activity using a dual-luciferase reporter assay. The relative luciferase activities were expressed as the ratio of the pRL-tk reporter activity to the pGL3 control plasmid activity.

**Quantitative RT-PCR.** A Verso cDNA synthesis kit (Thermo) was used for reverse transcription in a 20 µl reaction mixture containing 1 µg RNA, 4 µl 5× buffer, 2 µl dNTP mix, 1 µl RT enhancer, 1 µl enzyme mix, and either 1 µl oligo-dT primer or 1 µl Uni12 (an IAV genome-specific primer). The reverse transcriptase reaction was carried out at 70°C for 5 min, 50°C for 60 min (Uni12: 42°C for 60 min), and then 95°C for 2 min. qPCR was performed in a 20 µl mixture containing 5 µl cDNA, 10 µl THUNDERBIRD SYBR qPCR Mix (Toyobo), 1 µl forward primer, 1 µl reverse primer,
and 3 µl distilled water. The reaction conditions were 95°C for 5 sec and 60°C for 30 sec for 40 cycles of amplification.

**Isolation of murine bronchial and alveolar epithelial cells.** Female C57BL/6 mice (weight 17-20 g) were intranasally inoculated with 10^3 PFU of PR8 strain virus. At 0 to 7 days post-infection, primary bronchial and alveolar epithelial cells were isolated as described previously (17-19). B6 mice were sacrificed by an overdose of mixed anesthesia (0.75 mg/kg medetomidine, 4 mg/kg midazolam and 5 mg/kg butorphanol tartrate). They were exsanguinated by cutting the inferior vena cava. The lungs were perfused with 10 ml 0.9% NaCl using a 10 ml syringe fitted with a 21 gauge needle through the right ventricle until the lungs were visually free of blood. A 20 gauge intravenous catheter was inserted into the trachea and secured tightly with a suture. The lungs were filled with 1.5 ml Dispase (Corning) through the tracheal catheter. Low-melting point agarose (1%, 0.2 ml, stored in a 45°C water bath) was infused through the catheter. The lungs were immediately covered with crushed ice, incubated for 2 min, removed from the ice, and incubated for 45 min at room temperature. They were transferred to 4 ml DMEM containing 1% penicillin/streptomycin, 25 mM HEPES, 10% FCS, and 100 µl of 1 mg/ml DNase (Sigma-Aldrich). The digested tissue was homogenized with gentleMACS (Miltenyi Biotec) and successively filtered through 70 µm and 40 µm Falcon cell strainers. The filtered suspension was centrifuged at 1,300 rpm for 8 min at 8°C.

The cells were incubated with 1 µg biotinylated anti-CD45, 0.5 µg biotinylated anti-CD31, 1 µg biotinylated of anti-CD16/32 and 0.5 µg biotinylated anti-CD90.2 for 20 min at 4°C. The cells were washed with MACS buffer (Miltenyi Biotec) and
centrifuged at 1,300 rpm for 5 min at 8°C. The pellet was resuspended with MACS buffer and incubated with 20 µl anti-biotin Microbeads (Miltenyi Biotec) for 20 min at 4°C. The cells were again washed and centrifuged at 1,300 rpm for 5 min at 8°C. The cell suspensions were added to LS Columns (Miltenyi Biotec) attached to a MidiMACS Separator (Miltenyi Biotec). The columns were washed three times with 3 ml MACS buffer, and the eluates were collected in sterile tubes.

Western blot analysis. The cells were mixed with SDS sample buffer and heated for 5 min at 98°C. The lysates were separated by SDS-PAGE on an acrylamide gel and blotted onto a polyvinylidene difluoride membrane (PVDF; Millipore). Immunoblot analyses were performed according to a standard protocol using Tris-Buffered Saline (TBS) containing 0.1% Tween20 and 5% skimmed milk as a blocking solution and for antibody dilution. Antibody dilutions used were as follows: anti-GALNT3 antibody (Sigma-Aldrich), 1/1,000 dilution; anti-NP antibody, 1/1,000 dilution; anti-tubulin antibody, 1/1,000 dilution; and HRP-conjugated secondary antibodies, 1/10,000 dilutions. The antibodies were visualized with ECL Prime Western Blotting Detection Reagents (GE Healthcare) and exposed in an ImageQuant LAS-4000 imager (Fujifilm). The protein levels on the Western blots were measured by densitometric scanning of the corresponding bands using Image Reader LAS-4000 software. The densitometric values for tubulin were used to standardize for equal protein loading among the samples.

Three-dimensional cell culture. Primary HBECs were obtained from a commercial source (Lonza; CC-2540S) and cultured in growth medium (Lonza) supplemented with a B-ALI Medium SingleQuot Kit in T25 flasks. After two passages, the HBECs were
placed in the upper chamber of transwell plates in differentiation medium (Lonza) and maintained for 30 days. During culture, the cells differentiated into ciliated cells and goblet cells, and increasing amounts of mucus were secreted on the surface of the cells.

**Lectin microarray analysis.** Lectin microarray analysis (LecChip™) was performed as previously described (20, 21) using membrane fractions extracted from IAV-infected A549 and BEAS-2B and recombinant GALNT3-expressing BEAS-2B cells. Briefly, a small aliquot of the protein fraction (200 ng) was labeled with Cy3-succinimidyl ester (Cy3-labeled glycoprotein). The LecChip™ lectin chip with 45 lectins (GP BioSciences) was incubated with the Cy3-labeled glycoprotein solution (100 μl) at concentrations of 0.25 and 0.5 μg/ml in probing buffer at 4°C until the binding reached equilibrium. The net intensity value for each spot on the microarray was calculated by subtracting a background value from the signal intensity, and then the net signal intensity values of the three spots were averaged. The lectin microarray data for each cell type were processed by the microarray system using a max-normalization procedure after a gain-merging process.

**Minireplicon assay.** HEK293T cells were seeded in 12-well plates and transfected with plasmids containing 0.125 μg pCAGGS-PA, 0.125 μg pCAGGS-PB1, 0.125 μg pCAGGS-PB2, 0.125 μg pCAGGS-NP and 0.5 μg pPolI-CAT-WSN minigenome template using Lipofectamine2000. At 24 h post-transfection, the cells were lysed, and the lysates were prepared for chloramphenicol acetyltransferase (CAT) assay using a CAT ELISA kit (Roche).
Primary mouse embryo fibroblast cells. Primary MEFs were isolated from E17 wild-type and galnt3-KO mouse embryos by trypsin digestion at 37°C for 10 min. The cell suspension was cultured in DMEM with 10% FCS. After genotyping the embryos, the MEF cells were seeded in 12-well culture dishes and inoculated with PR8 (H1N1) and Suite (H3N2) viruses with MOI = 3.0 and 1.0, respectively.

Infection of mice. Wild-type (WT) and KO (Galnt3^{-/-}) C57BL/6 mice (6- to 7-week-old females) were challenged with 10^3 PFU of PR8 strain virus. For each mouse, 30 µl of virus solution diluted in PBS was inoculated intranasally. The same volume of PBS was used for mock infection. For each experimental group, the body weights of 5 mice were monitored daily. Lung homogenates were collected at 0 to 7 days post-inoculation (d.p.i) to measure the viral titers activated in vivo by focus formation assay. Three mice were used for each experimental group, and samples of their right or left lungs were separately collected from individual mice. For histopathological examinations, WT and galnt3-KO mice were infected with 10^3 PFU of the PR8 strain and autopsied at 6 d.p.i. Three mice were used for each experimental group.

Histology. For light microscopy analysis, female mice were anesthetized by intraperitoneal injection of mixed anesthesia and fixed with Bouin solution at 4°C overnight. Dissected right or left lungs were embedded in paraffin. The sections were stained with hematoxylin and eosin (H-E) according to a standard protocol. Histological evaluations were carried out by the New Histo Science Laboratory Company. The inflammation symptoms of the lungs were scored based on the method of a previous study (22).
Primer and probes. The primers and probes used in this study are available upon request.

Ethics statement. Experimental infection of the galnt3-KO mice was conducted following the guidelines for the Care and Use of Laboratory Animals of the Ministry of Education, Culture, Sports, Science and Technology, Japan. Animal experiments were carried out at the Institute for Virus Research in Kyoto University (IVRKU) (protocol numbers D15-11, D14-11, and D13-07) after approval by the Committee on the Ethics of Animal Experiments of IVRKU in accordance with the guidelines for animal experiments at IVRKU.

Results

Downregulation of miRNAs targeting GALNT3 mRNA during the early stage of influenza A virus infection. An increasing number of studies have suggested that cellular miRNAs play an important role in various host cell responses to viral infection (23-25). To understand the host cell responses during the early stage of IAV infection, we performed an miRNA microarray analysis using the human alveolar adenocarcinoma cell line, A549 cells, infected with influenza A/Puerto Rico/8/34 H1N1 (PR8) virus. We isolated the cellular RNAs at 0.5, 1.5 and 4.5 h post-infection and detected significant changes in the global profile of miRNA expression after infection with IAV. Specifically, we detected 23 miRNAs that were differentially expressed at a statistically significant level ($p < 0.05$) between IAV-infected cells and uninfected control cells (Fig.
Among the differentially expressed miRNAs, 20 and 3 miRNAs were significantly downregulated or upregulated at 4.5 h postinfection, respectively. Heat map analysis showed the changes in the miRNA expression during the observation periods in IAV infected cells (Fig. 1A). By using IPA (Ingenuity(R) Systems) to ensure the quality of the data, we predicted the pathways controlled by the miRNAs and identified two Homo sapiens (hsa)-miRNAs, miR-17-3p and miR-221, that showed a high degree of homology to the sequences of an UDP-GalNAc transferase, GALNT3, mRNA.

GALNT3 belongs to a largest family of UDP-GalNAc transferases catalyzing the O-glycosylation of mucin or mucin-like proteins. Although the involvement of GALNT3 in viral infections has not been demonstrated yet, recent evidences showed that the UDP-GalNAc transferase families may play important roles in viral replication (26, 27). Therefore, we next investigated the regulation of the GALNT3 in the IAV infection. At first, we analyzed the expression of GALNT3 mRNA by real-time PCR after the transfection of the oligonucleotide mimicking the identified miRNA into HEK293T cells to investigate whether miR-17-3p and miR-221 actually regulate the expression of GALNT3 mRNA. As shown in Fig. 1C, the mimic sequences significantly decreased the expression of GALNT3 mRNA. We next searched for the putative miRNA-binding sites in the GALNT3 gene and found that the 3’ UTR of GALNT3 mRNA contains the putative sites for both miR-17-3p and miR-221 (Fig. 1B). To confirm the miRNA binding and their function in regulating the GALNT3 gene, we designed a reporter plasmid, pRL-tk-GALNT3-3’UTR, in which the 3’ UTR of GALNT3 mRNA was subcloned downstream of the luciferase open reading frame. The mutant plasmids, pRL-tk-GALNT3-3’UTR 17-3p mut and 221 mut, which contain point mutations in the putative binding sites for miR-221 and miR-17-3p, were also
generated (Fig. 1B). HEK293T cells were transfected with mimic oligonucleotides of miR-17-3p or miR-221, and then the pRL-tk-GALNT3 vectors, either wild-type or the mutants, were introduced. As shown in Fig. 1D, the expression of miRNA mimic sequences significantly reduced the luciferase activity in cells transfected with the wild-type pRL-tk-GALNT3-3’UTR plasmid. In contrast, the luciferase activity of the 3’ UTR mutant plasmids was not decreased in the cells transfected with the mimic sequences corresponding to the mutants (Fig. 1D). These results demonstrated that the binding sites in the 3’ UTR of GALNT3 mRNA are critical for the miR-17-3p and miR-221-mediated repression of luciferase activity from the pRL-tk vectors and also that both miR-17-3p and miR-221 could be the regulatory miRNAs for GALNT3 mRNA in IAV-infected cells.

Replication of influenza A virus rapidly induces the expression of GALNT3 mRNA.

To confirm the downregulation of miR-17-3p and miR-221 by IAV infection, A549 cells were infected with PR8 virus, and the expression levels of the miRNAs were monitored for up to 4.5 h post-infection. Consistent with the microarray analysis, both miR-17-3p and miR-221 expression were significantly downregulated by the infection (Fig. 2A). We next investigated whether IAV infection actually affects the expression of GALNT3. We utilized real-time PCR to detect the mRNA levels of GALNT3 in A549 and BEAS-2B cells infected with the PR8 virus. At an MOI of 3.0, the expression of GALNT3 mRNA was significantly upregulated in the cells by 4.5 h post-infection (Fig. 2B). Notably, BEAS-2B cells appeared to vastly induce the expression of GALNT3 mRNA by IAV infection, because of low level expression in the uninfected status. The infection of A549 cells with H1N1 (A/Beijing/262/95) and H3N2 (A/Panama/2007/99
and A/Suita/82/2011) IAV (MOI = 3.0) was also shown to induce GALNT3 mRNA by
4.5 h post-infection (Figs. 2C, D and E). We confirmed the increase of GALNT3 protein
in the bronchial and alveolar epithelial cells isolated from C57BL/6 mice that were
inoculated with the PR8 virus at $10^3$ PFU. As shown in Fig. 2F, the expression of
GALNT3 protein gradually increased with the replication of the IAV in lung cells
during the observation period of 7 days post-inoculation. We also observed that
infection with the PR8 virus did not induce the upregulation of GALNT1, GALNT2,
GALNT6, or GALNT7 (Fig. 2G). These observations suggest that both GALNT3
mRNA and protein are specifically upregulated by IAV infection.

We next sought to determine whether IAV replication in the cells is essential for
the upregulation of GALNT3 mRNA. To this end, the UV-irradiated PR8 virus was
inoculated into A549 cells, and the expression of GALNT3 mRNA was determined at
4.5 h post-infection. An immunofluorescence analysis with anti-NP antibody revealed
that the UV-irradiated PR8 virus could not replicate in the cells (Fig. 2H). Notably,
under this condition, the increased expression of GALNT3 mRNA was not observed in
the cells (Fig. 2I). We showed that the adsorption of UV-irradiated virus to the cells was
not different from that of wild-type virus, suggesting that the replication of IAV within
the cells is necessary for the upregulation of GALNT3.

GALNT3 expression is associated with mucin production and the modification of
O-linked glycosylation in IAV-infected cells. The aforementioned results indicate
that IAV infection rapidly induces GALNT3 expression in infected cells. Because
GALNT3 initiates the O-glycosylation of mucin or mucin-like proteins, it is
conceivable that the upregulation of GALNT3 by IAV replication may lead to mucin
production, as well as to O-glycosylation modification, in infected cells. To understand the roles of the induction of GALNT3 in IAV-infected cells, we next monitored mucin production in differentiated human bronchial epithelial cells (HBECs) infected with IAV using an air/liquid interface culture system. Previous studies have revealed that the HBECs gradually differentiate into ciliated epithelial and goblet cells. It has been shown that goblet cells are a main source of mucins in the airways and that IAV primarily infects the goblet cells that express an abundance of MUC5AC (28). In fact, we detected IAV infection only in the MUC5AC-positive goblet cells in the HBEC culture (Fig. 3A).

To investigate mucin production following IAV infection, the HBECs infected with the WSN strain were analyzed by real-time PCR. This analysis revealed that the infection significantly induced the expression of the mRNAs encoding GALNT3 and MUC1 (Figs. 3B and C). There was no difference between the numbers of goblet cells in the infected and uninfected differentiated HBECs, suggesting that the production of GALNT3 following IAV infection is most likely associated with the mucin production in infected goblet cells.

Next, to understand whether the GALNT3 expression modifies O-linked glycosylation, we performed lectin microarray analysis (LecChip™) with the membrane proteins from the IAV-infected and uninfected A549 and BEAS-2B cells. In addition to the alteration of glycosylation by the IAV infection, we also monitored the modification in the BEAS-2B cells stably expressing GALNT3 (15). The binding of Cy3-labeled glycoprotein was performed in triplicate for the 45 different lectins. The data were then analyzed with the Array-Pro Analyzer (Media Cybernetics). The results were shown with the gain set to register a maximum net intensity < 50,000 for the most intense spots. In the IAV-infected cells, we observed that the lectins that recognize sialic acids, such as
MAL (Maackia amurensis lectin), MAH (Maackia amurensis hemagglutinin), and TJA-I (Trichosanthes japonica agglutinin I), were significantly decreased, indicating that the membrane-bound sialic acids are presumably cleaved by the viral neuraminidase (NA) in the infected cells (Fig. 3D and Supplementary Table 1). In association with the cleavage of the membrane-bound sialic acids, microarray analysis revealed that lectins specifically recognizing O-linked glycosylation, including RCA120 (Ricinus communis agglutinin 120), BPL (Bauhinia purpurea lectin), TJA-II (Trichosanthes japonica agglutinin), PNA (Peanut agglutinin), and WFA (Wisteria floribunda lectin), were markedly increased in the cells infected with the PR8 virus (Fig. 3D and Supplementary Table 1). Notably, the membrane glycoproteins from the cells stably expressing GALNT3 showed significant increases mainly in the lectins recognizing O-linked glycosylation, of which upregulation was also observed in the IAV-infected cells (Fig. 3E and Supplementary Table 1). These observations suggest that the upregulation of GALNT3 is involved in the modification of O-linked glycosylation, as well as in mucin production, in IAV-infected cells.

Expression of GALNT3 positively regulates influenza virus replication. A previous study has suggested that during IAV infection, mucin acts as an immobilization substrate for the virus on the cell surface (29). Furthermore, a recent study revealed that increased MUC5AC secretion appears to play a protective role against influenza virus infection (12). However, it remains unknown whether the modification of mucin-type O-linked glycosylation in infected cells affects IAV replication, as well as viral production. Therefore, we next sought to determine the effect of GALNT3 expression on IAV replication. First, we monitored the time course of the expression levels of
GALNT3 mRNA and viral genomic RNA in A549 and BEAS-2B cells after infection with the PR8 virus. As shown in Figs. 4A and B, the induction of the GALNT3 mRNA was highly correlated with the release of viral genomic RNA in the culture supernatants, suggesting that the expression of GALNT3 may be associated with IAV replication in these cells.

To elucidate the role of GALNT3 in IAV replication, the effects of small interfering RNAs (siRNAs) against GALNT3 and of the oligonucleotides mimicking miR-17-3p and miR-221 on PR8 viral replication were examined in BEAS-2B cells. We examined the level of viral genomic RNA and the viral titers in the infected cells at 4.5 and 24 h after inoculation. The effects of GALNT3 and GALNT1 knockdown by the siRNAs and mimic miRNAs were verified (Figs. 4C and D). At 4.5 h post-inoculation, the knockdown of GALNT3, but not GALNT1, markedly reduced the viral genomic RNA and viral titer by approximately 50% and 75% compared to the control cells, respectively, (Fig. 4E). Consistent with this result, the treatment with the sequences mimicking miR-17-3p and miR-221 prior to viral inoculation also reduced the level of viral RNA and the viral titer compared with untreated cells (Fig. 4E). However, we could not detect significant differences in the viral genomic RNA and viral titer at 24 h post-infection (Fig. 4F). We found that the overexpression of GALNT3 did not appear to significantly influence IAV replication at 4.5 h post-inoculation (Figs. 4G and H), indicating that the expression level of endogenous GALNT3 is sufficient to stimulate viral replication in the cells. These results suggested that the upregulation of GALNT3 significantly affects the efficiency of early infection of IAV.

We next investigated whether GALNT3 is directly involved in IAV polymerase activity. To this end, we used an IAV minireplicon assay system, which is the
reconstitution of the viral ribonucleoprotein complex three polymerase subunits, NP, and synthetic viral RNA encoding the CAT gene in transfected cells. Prior to transfection with the minireplicon plasmids, we introduced siRNAs either GALNT3 or GALNT1 siRNA into HEK293T cells and measured the CAT activity in the cells at 24 h after transfection. Notably, treatment with GALNT3 siRNA, but not GALNT1 siRNA, significantly reduced the CAT activity compared to the control scrambled siRNA (Fig. 5). Together, these observations suggest that the upregulation of GALNT3 affects IAV polymerase activity in the cells, thereby facilitating viral replication.

**Galnt3**<sup>−/−</sup> mice reveal the dual function of GALNT3 during influenza virus infection.

To confirm the effect of GALNT3 expression on IAV replication, we obtained Galnt3<sup>−/−</sup> mice (30) and analyzed IAV replication in MEF cells. We used PR8 and H3N2-Suita viruses to infect MEF cells derived from wild-type and Galnt3<sup>−/−</sup> mice and monitored the levels of viral genomic RNA and titers for up to 4.5 h post-infection. As shown in Figs. 6A and B, both the viral genomic RNA and the viral titer were significantly decreased in the Galnt3<sup>−/−</sup> mouse MEF cells from the early time points after inoculation, suggesting that GALNT3 may positively regulate IAV replication during the early stage of infection.

We experimentally infected Galnt3<sup>−/−</sup> mice with the PR8 virus. The virus was intranasally inoculated into 6- to 7-week-old WT and Galnt3<sup>−/−</sup> mice at 10<sup>3</sup> PFU. We confirmed the lack of GALNT3 expression in the lungs of Galnt3<sup>−/−</sup> mice by Western blot analysis (Fig. 7A) and observed no histological difference between WT and Galnt3<sup>−/−</sup> mouse lungs before inoculation (Fig. 7B). Following inoculation with the PR8 virus, interestingly, a significant body weight loss (< 40%) occurred in all KO mice by 7
d.p.i., whereas WT mice showed only a <15% reduction by 14 d.p.i. (Fig. 7D).

Furthermore, all KO mice inoculated with $10^3$ PFU of PR8 virus died by 11 d.p.i. In contrast, no fatality was observed in WT mice during the observation period of 14 d.p.i. (Fig. 7E).

Figure 7C shows the histopathology of lungs of mice infected with $10^3$ PFU of the PR8 virus. The Galnt3$^{-/-}$ mice showed alveolus and peribronchial inflammation with the infiltration of inflammatory cells, especially macrophages, and also developed alveolitis by 6 d.p.i. In contrast, the lungs of WT mice infected with the same virus exhibited significantly reduced levels of inflammation (Fig. 7C). To verify the viral propagation in the lungs, lung homogenates were harvested every day and used to determine the viral titers. Although the lungs of Galnt3$^{-/-}$ mice exhibited delayed increases in the viral titers until 3 d.p.i. (Fig. 7F), the viral titer in the lungs of KO mice rapidly increased and were much higher than those in the lungs of WT mice after 4 d.p.i. (Fig. 7G). These data suggested the efficient propagation of the virus in the lungs of Galnt3$^{-/-}$ mice.

**Discussion**

In this study, we demonstrated that IAV upregulates the expression of GALNT3 via the miRNA machinery in human lung epithelial cell lines and HBECs. This report is the first to show that IAV infection affects the expression of GalNAc transferase, which is responsible for the initial step of mucin-type O-glycosylation. We also found that the upregulation of GalNAc transferase is involved in both O-linked glycosylation and the IAV replication in infected cells. Although it has been known that the alteration of mucin production and/or the O-glycosylation of cellular receptors is critical for the adsorption of virions onto the cell surface, elucidating the role of mucin-type
glycosylation in viral replication may provide new insights into the life cycle of IAV. Understanding the initial step of IAV infection is important for the development of a strategy to suppress the multiplication of IAV in vivo. We used an miRNA microarray analysis to investigate the cellular responses during the early steps of IAV infection and found that several miRNA pathways were markedly altered in human lung epithelial carcinoma cells (Fig. 1). Recent studies have demonstrated the changes in miRNA expression that are directed by IAV infection (23, 25). Buggele et al. revealed the induction of primary miRNA expression in human respiratory cell lines, including IAV-infected A549 and BEAS-2B cells, but they detected miRNAs beginning only at 8 h post-infection (23). Furthermore, many studies have mainly focused on the regulation of antiviral responses by the miRNA machinery in the cells infected with viruses, including IAV (31). In this study, we focused on the miRNAs that mediate post-translational modifications, such as glycosylation, of cellular proteins during the early stage of IAV infection and investigated two specific miRNAs, miR-17-3p and miR-221, both of which were significantly downregulated by IAV infection. We found that both miRNAs target the GalNAc transferase GALNT3 and are downregulated as early as 4.5 h post-infection. Note that it is unclear how viral infection suppresses these miRNAs in infected cells. Because these miRNAs are downregulated at an early time point following infection, it is conceivable that host responses to virus infection, such as innate immune responses, may trigger the suppression of these miRNAs in infected cells.

We demonstrated that the 3' UTR of GALNT3 mRNA is the target of the miRNAs and that the expression level of GALNT3 mRNA is actually reduced by the expression of the miRNA mimics (Figs. 1 and 2), providing evidence for the miRNA-mediated
regulation of GALNT3 expression. In previous studies, it has been revealed that the both miRNAs regulate cellular molecules other than GALNT3. Interestingly, miR-17-3p is also thought to target another UDP-GalNAc transferase, GALNT7, mRNA and may induce the development of hepatocellular carcinoma (32). This observation suggests that miR-17-3p may be a key regulator of GalNAc transferase expression in other cell or tissue types, although we did not observe changes in GALNT7 mRNA expression in A549 cells infected with IAV (Fig. 2). In addition, miR-17-3p has been reported to have several potential targets, including GFRA2 (GDNF family receptor alpha 2) (33), Par4 (Prostate apoptosis response-4) (34), TIMP3 (TIMP metallopeptidase inhibitor 3) (35), MDM2 (murine double minute 2) (36), and Olig2 (Oligodendrocyte transcription factor) (37), all of which are known to be involved in cell proliferation or viability. In this study, however, we did not assess the involvement of these genes in IAV replication. On the other hand, it is noteworthy that the expression of miR-221 is also downregulated in HEBCs infected with RSV, resulting in the upregulation of nerve growth factor (NGF) and the promotion of viral replication in infected cells (24). This finding suggests that the miR-221 pathway may be commonly regulated during infection with respiratory viruses, such as IAV and RSV. A recent study showed that miR-221 accentuates the effect of interferon (IFN) on the hepatitis C virus (HCV) by targeting SOCS1 and SOCS3 (38). Furthermore, miR-221 is known to be an oncogenic miRNA that targets many genes associated with cellular proliferations, including PTEN (39), p27 (Kip1) (40), and TIMP-2 (41). Therefore, it would be interesting to investigate whether the downregulation of miR-221 also affects the expression of such molecules in IAV-infected cells, particularly respiratory epithelial cells.

Our observation suggested the functional role of the O-linked glycosylation
modification in the early step of IAV infection. In this study, we demonstrated the altered expression of GALNT3 protein in mouse lung cells infected with IAV, but not in infected cell lines, such as A549 and BEAS-2B cells, was likely due to its basal expression level in the cell lines. Nevertheless, mucin production and O-linked glycosylation were detected in cultured cells infected with IAVs (Fig. 3). The lectin microarray analysis demonstrated similar alterations to the O-linked glycosylation between the cells infected with IAV and those stably expressing recombinant GALNT3, strongly suggesting that IAV infection affects the posttranslational modification and formation of mucin-type glycoproteins by regulating the GALNT3 machinery. Our results suggest a mechanism that explains how O-linked glycosylation modification or mucin production is rapidly initiated in respiratory epithelial cells infected with IAV, which could be the first example of the molecular regulation of mucin production during respiratory virus infections.

Recent evidence has demonstrated that O-linked glycosylation modifications in viral-infected cells are critically involved in the various stages of infection. In many studies, glycosylation has been shown to affect the viral attachment or penetration steps via the modification of cellular receptors or viral envelope glycoproteins. For instance, the O-linked glycoproteins of α2,3- or α2,6-linked sialic acids were shown to play important roles during infection by IAV and other viruses, including the coxsackievirus A24 variant and Enterovirus 70 (42-45). Furthermore, the envelope proteins of many viruses, such as human immunodeficiency virus type 1, HCV, Ebola virus, and herpes simplex virus type 1, are shown to be modified by O-linked glycosylation, which influences the attachment of viral virions to the cell surface (42, 46-48). These observations suggest that the O-linked glycosylation is an important modification in
viral infected cells that directly or indirectly controls the various steps of viral replications. It is therefore of interest to investigate changes in GalNAc transferase expression during other viral infections to understand the regulation of O-linked glycosylation in infected cells.

In this study, we showed that UV-treated IAV virions could not induce GALNT3 expression in A549 cells (Fig. 2). Furthermore, the upregulation of GALNT3 was appeared to be correlated with the multiplication of IAV (Fig. 4). These findings suggested that viral replication, but not the cellular association of viral particles, is necessary for the induction of GALNT3 and also that the upregulation of GALNT3 may affect the IAV replication. In fact, we demonstrated using siRNA and mimic miRNA that the expression of GALNT3 markedly increases the efficiency of the virus replication, although the effect of the GALNT3 knockdown was modest. In addition, we showed that the replication of IAV is significantly impaired in MEF cells derived from the galnt3-KO mice (Fig. 6). From all these observations, it could be reliable that the expression of GALNT3 facilitates the viral replication in the early time points postinfection, suggesting an important role for GALNT3 in IAV infection. The upregulation of GALNT3 in IAV-infected cells (Fig. 4), in addition to the IAV minigenome assay (Fig. 5), revealed that O-linked glycosylation via GALNT3 expression might be required at multiple steps of the viral life cycle. It is possible that the O-linked glycosylation of certain host factors is involved in late steps of the viral replication, including nuclear transport, assembly, and viral RNP budding.

GALNT3 is conceivably involved in IAV replication via the O-linked glycosylation of specific cellular proteins. The O-linked glycosylation of specific cellular substrates is known to affect various cellular processes, such as protein folding,
cell adhesion, signal transduction, protein trafficking, cell proliferation, apoptosis, and cancer (2, 49, 50). At present, only a few specific substrates for GALNT3 have been identified. Fibroblast growth factor 23 (FGF23), which is a bone-derived hormone that regulates and is regulated by the blood levels of phosphate and active vitamin D (51), is a well-known cellular substrate of GALNT3. The posttranslational glycosylation of FGF23 by GALNT3 results in the prevention of FGF23 proteinase processing (52), suggesting that GALNT3 is important for controlling the pathophysiological level of FGF23 (53, 54). Although *galnt3*-KO mice exhibit testicular calcifications and male infertility (30), it is unlikely that FGF23 is directly involved in the replication of IAV due to the fact that the expression of FGF23 has not been demonstrated in respiratory epithelial cells. However, a recent study revealed that GALNT3 suppression results in the up- or downregulation of numerous genes associated with the pathways involved in transcriptional regulation, signal transduction, cell proliferation and immune and inflammatory responses, as well as mucin O-glycosylation modification, in epithelial ovarian cancer cells, demonstrating that GALNT3 contributes to various cellular processes through the O-glycosylation of many unknown substrates (55). In this respect, it is conceivable that GALNT3 affects IAV replication by modifying the O-linked glycosylation of unknown cellular factor(s) that may be involved in the activity of viral polymerase. In fact, alteration of the O-linked glycosylation is known to be correlated with the anti-viral response to certain virus infections. It has been recently reported that variants of a GalNAc transferase, GALNT8, may contribute to the response to IFN therapy against chronic HCV infection and that the overexpression of GALNT8 attenuated IFN-α-induced gene transcription via the IFN-stimulated response element (26). We are currently working to identify specific substrates of GALNT3 in the
respiratory tracts to better understand the mechanism underlying the effect of GALNT3 on IAV replication during the early stages of infection.

In this study, we demonstrated that compared to WT mice, galnt3-KO mice exhibit high mortality with severe pathological alterations in the lungs following infection with PR8 (Fig. 7). Interestingly, the viral titers in the lungs of galnt3-KO mice were significantly higher than those of WT mice after 4 d.p.i. Considering that the fact mucin plays essential roles in airway defense against microbial infection and propagation in vivo, it is conceivable that GALNT3 exerts a dual function during IAV infection; GALNT3 may enhance the intracellular viral replication and may control viral propagation in vivo, for IAV infection. We are now conducting in vivo experiments to understand the dual function of GALNT3 and mucin in IAV infection.

In conclusion, the results of our study may improve our knowledge of the regulation of IAV replication during the early stage of viral infection, as well as our understanding of the role of mucin production in IAV infection. Understanding the regulation of IAV replication via GALNT3 expression, especially regarding specific substrates of GALNT3, would be useful for establishing strategies to control IAV multiplication in vivo and for developing novel anti-influenza virus approaches.

Acknowledgements

We thank Atsuyasu Sato for technical assistance with the isolation of murine bronchial and alveolar epithelial cells. This study was supported in part by KAKENHI Grant Numbers 26253027 and 26670225 (KT); the Core-to-Core Program A, Advanced Research Networks (KT); Basic and Grant-in-Aid for JSPS Fellows (13J05979) (SN)
from the Japan Society for the Promotion of Science (JSPS); the Science and Platform Technology Program for Innovative Biological Medicine (KT) from the Ministry of Education, Culture, Sports, Science & Technology (MEXT); and grants from the Sumitomo Foundation (KT) and the Daiichi Sankyo Foundation of Life Science (KT).
References


Figure Legends

Figure 1. Downregulation of miR17-3p and miR-221 during the early stage of IAV infection. (A) A heat map comparing the fold-changes of microRNAs with significantly higher (red) or lower (green) expression in A549 cells infected with PR8 virus at an MOI of 1.0. The p-values of the fold-changes are indicated. (B) Sequences of predicted miR-17-3p and miR-221 binding sites in the 3’ UTR of GALNT3 mRNA. The black letters below the predicted binding sites (boxed) indicate the nucleic acid substitutions in the mutant plasmids used for the luciferase assay. (C) The reduction of GALNT3 mRNA expression by miR-17-3p and miR-221 mimic oligonucleotides. HEK293T cells were transfected with oligonucleotides mimicking miR-17-3p and miR-221, and the expression of GALNT3 mRNA was detected by real-time PCR. The relative expression levels of GALNT3/GAPDH are shown (control = 1.0). Control: scrambled control miRNA. (D) miR-17-3p and miR-221 target the 3’ UTR of GALNT3 mRNA. Plasmids containing either point mutations in the putative miR-17-3p and miR-221 binding sites or miR-17-3p mut and miR-221 mut were transfected into HEK293T cells after the introduction of the mimic oligonucleotide. The luciferase activity in the transfected cells was monitored 24 h after transfection. The y-axis indicates the luciferase activity of the pRL-tk reporter relative to that of the pGL3 control plasmid. All values are expressed as the mean (n > 3) ± SEM. Statistical significance was analyzed by Student’s t-test. *p < 0.05.

Figure 2. Upregulation of GALNT3 mRNA by IAV replication. (A) Downregulation of miR-221 and miR-17-3p in A549 cells infected with PR8 virus. A549 cells were infected with PR8 virus at an MOI of 3.0, and the expression levels of
miR-221 and miR-17-3p were monitored at the indicated time points by real-time RT-PCR. (B to E) IAV infection upregulates GALNT3 mRNA. A549 and BEAS-2B cells were infected with H1N1 PR8 virus at an MOI of 3.0 (B). A549 cells were infected with H1N1 Beijing (C), H3N2 Panama (D), and H3N2 Suita viruses (E) were at an MOI of 3.0. The expression of GALNT3 was monitored by real-time PCR at the indicated times post-infection. Samples were normalized to GAPDH mRNA and the relative expression levels of GALNT3 are shown (0 h = 1.0). (F) Upregulation of GALNT3 protein in bronchial and alveolar epithelial cells isolated from IAV-infected mice. After the intranasal infection of C57BL/6 mice with H1N1 PR8 virus at 10³ PFU, the expression of the GALNT3 and IAV NP proteins in lung cells was detected by Western blotting. The line graphs indicate the relative band intensities of each protein compared to that of tubulin. The intensities of the bands were determined using a LAS-4000 imager (Fujifilm). Left, GALNT3 protein; Right, IAV NP protein. (G) IAV infection does not change the mRNA expression levels of GALNT1, 2, 6 or 7. A549 cells were infected with PR8 virus at an MOI of 3.0, and the mRNA expression levels of GALNT1, 2, 6 and 7 were monitored at the indicated times by real-time RT-PCR. Samples were normalized to GAPDH mRNA, and the relative expression levels of GALNTs are shown (mock = 1.0). (H and I) Viral replication is necessary for the upregulation of GALNT3 mRNA. A549 cells were inoculated with UV-irradiated PR8 virus (UV-PR8) at an MOI of 3.0, and the replication of the inoculated virus was detected by immunofluorescence analysis using an anti-NP antibody at 12 h post-infection. Scale bar, 30 μm. The expression of GALNT3 mRNA was determined via real-time RT-PCR. All values are expressed as the mean (n > 3) ± SEM. Statistical significance was analyzed by Student’s t-test. *p < 0.05, **p < 0.01.
Figure 3. GALNT3 affects mucin production and O-linked glycosylation in IAV-infected cells. (A) IAV infects goblet cells expressing MUC5AC. Differentiated HBECs were infected with WSN virus at an MOI of 3.0. Nine h after inoculation, virus-infected cells were detected by immunofluorescence analysis using anti-MUC5AC and anti-NP antibodies. Scale bar, 30 μm. A high magnification image of an infected cell (square) is also shown. (B and C) The relative expression levels of GALNT3 (B) and MUC1 (C) mRNAs in HBECs were detected at 9 h post-infection. Statistical significance was analyzed by Student’s t-test. *p < 0.05. (D and E) Lectin microarray analysis of PR8 virus-infected A549 (upper) and BEAS-2B cells (lower) (D) and recombinant GALNT3-expressing BEAS-2B cells (E). The cells were infected with PR8 virus at an MOI of 3.0, and samples were isolated at 12 h post-infection. Each graph was generated according to lectin group. The lectin groups are colored according to their recognition of the sugar chains indicated to the right of the graphs. Fuc, L-fucose; Man, D-mannose; SA, sialic acid; GlcNAc, N-acetyl-D-glucosamine; Gal/GalNAc, D-galactose/N-acetyl-D-galactosamine. The membrane fractions extracted from infected and uninfected cells were labeled and incubated with a LecChip™ representing 45 lectins. The net intensity value for each spot of the microarray was calculated by subtracting a background value from the signal intensity. The net signal intensity values of three spots were averaged. All values are expressed as the mean (n > 3) ± SEM. *p < 0.05.

Figure 4. GALNT3 expression upregulates IAV replication. (A and B) Correlation between the expression of GALNT3 mRNA and viral replication. The induction of
GALNT3 mRNA and viral RNA expression in PR8 virus-infected A549 (A) and BEAS-2B cells (B) was monitored by real-time RT-PCR at the indicated time points. The viral NP segment was used for quantification. The virus was infected at an MOI of 3.0. The viral titers in the culture supernatants were determined by focus-forming unit assays. (C to F) Knockdown of GALNT3 mRNA reduces IAV replication. BEAS-2B cells treated with siRNAs against GALNT3 (siGALNT3) and GALNT1 (siGALNT1) and with mimic oligonucleotides (miR-17-3p and miR-221). At 48 h post-transfection, the levels of GALNT3 (C) and GALNT1 (D) were monitored by qRT-PCR. The cells treated with siRNA or mimic oligonucleotides were infected with PR8 virus at an MOI of 3.0, and the levels of the viral genome and viral titer in the culture supernatants were determined at 4.5 h (E) and 24 h (F) after infection by qRT-PCR and FFU assays, respectively. For viral RNAs, samples were normalized to GAPDH mRNA. The results are expressed in arbitrary units. The scramble siRNA (si control) was used as a control. (G) Overexpression of GALNT3. BEAS-2B cells were transfected with a human GALNT3-expression plasmid, and at 48 h after transfection, the level of GALNT3 mRNA was monitored by qRT-PCR. (H) GALNT3 overexpression does not affect IAV replication. Cells were infected with PR8 virus at an MOI of 3.0, and IAV replication was monitored by the level of the viral genome and the viral titer at 4.5 h post-inoculation. The values are presented as the mean ± SE of at least three independent experiments. *p < 0.05, **p < 0.01.

**Figure 5. Knockdown of GALNT3 mRNA affects IAV minigenome replication.** The IAV minireplicon assay was performed in HEK293T cells transfected with siGALNT3 and siGALNT1. Twenty-four hours after minigenome transfection, CAT activity was
determined using a CAT ELISA system. As a control, an empty vector (empty) was transfected instead of the minigenome plasmid. All values are presented as the mean (n > 3) ± SEM. Statistical significance was analyzed by Student’s t-test. *p < 0.05.

Figure 6. IAV replication in Galnt3−/− MEF cells. (A and B) The replication of PR8 (A) and Suita (B) viruses in MEF cells derived from WT and Galnt3−/− mice was monitored by the level of viral genomic RNA and the titer at the indicated times. Samples were normalized to GAPDH mRNA. +/+, WT; −/−, Galnt3−/− mice. All values are presented as the mean (n > 3) ± SEM. *p < 0.05.

Figure 7. The role of GALNT3 in IAV pathogenicity in vivo. (A) The expression of GALNT3 protein in WT and Galnt3−/− mice. The lungs of 6-week-old WT and KO mice were removed and subjected to Western blot analysis using anti-Galnt3 antibody. GALNT3: 73-kDa. (B) Histological analysis of the lungs of uninfected, 6-week-old WT and Galnt3−/− mice. The data were obtained by H-E staining (magnification, 10×). (C) Histopathological findings in the lungs of WT and Galnt3−/− mice infected with PR8 IAV. The data obtained by H-E staining (magnification, 4×) are shown. The inflammation scores of individual mice (n = 3) are shown at the bottom of each panel: 0, no apparent changes; 1, minimal changes or bronchiolitis; 2, bronchiolitis and/or slight alveolitis; 3, mild alveolitis with neutrophils, monocytes/macrophages, or lymphocytes; 4, moderate alveolitis. (D and E) WT and Galnt3−/− mice were intranasally inoculated with H1N1 PR8 virus at 10^3 PFU (n = 3). (D) Body weights were measured daily. Error bars represent standard deviations. (E) Survival curves of IAV-infected mice. Each experimental group consisted of 3 mice. d.p.i, days post-inoculation. (F and G) Viral
titers in the lungs of IAV-infected mice. Lung homogenates were obtained every day and were used for virus titration. For each day, 3 mice were used. Error bars represent standard deviations. Panels F and G are independent experiments. (F) Viral titers during the early inoculation periods up to 3 d.p.i.
### Table A

<table>
<thead>
<tr>
<th>Systemic Name</th>
<th>p-value</th>
<th>0.5 h</th>
<th>1.0 h</th>
<th>1.5 h</th>
<th>2.0 h</th>
<th>4.5 h</th>
<th>0.5 h</th>
<th>1.0 h</th>
<th>1.5 h</th>
<th>2.0 h</th>
<th>4.5 h</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-505-3p</td>
<td>0.036</td>
<td>1.21</td>
<td>1.00</td>
<td>1.79</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-520b</td>
<td>0.015</td>
<td>2.15</td>
<td>1.45</td>
<td>1.56</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1296</td>
<td>0.016</td>
<td>1.18</td>
<td>1.62</td>
<td>1.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-340-3p</td>
<td>0.001</td>
<td>-1.16</td>
<td>-2.26</td>
<td>-1.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-519a</td>
<td>0.003</td>
<td>-1.17</td>
<td>-1.20</td>
<td>-1.18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-29b</td>
<td>0.021</td>
<td>-1.20</td>
<td>-1.13</td>
<td>-1.42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-194</td>
<td>0.068</td>
<td>-1.11</td>
<td>-1.11</td>
<td>-1.54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1250</td>
<td>0.011</td>
<td>-1.16</td>
<td>-1.12</td>
<td>-1.49</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1274b</td>
<td>0.032</td>
<td>-1.28</td>
<td>-1.18</td>
<td>-1.53</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-424</td>
<td>0.008</td>
<td>-1.17</td>
<td>-1.11</td>
<td>-1.54</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-361-3p</td>
<td>0.029</td>
<td>-1.57</td>
<td>-1.44</td>
<td>-1.56</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1274a</td>
<td>0.035</td>
<td>-1.30</td>
<td>-1.20</td>
<td>-1.56</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-68</td>
<td>0.034</td>
<td>-1.11</td>
<td>-1.06</td>
<td>-1.59</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-022_v2.0</td>
<td>0.046</td>
<td>-1.12</td>
<td>-1.17</td>
<td>-1.62</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-326</td>
<td>0.044</td>
<td>-1.68</td>
<td>-1.68</td>
<td>-1.68</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-221</td>
<td>0.029</td>
<td>-1.16</td>
<td>-1.14</td>
<td>-1.82</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-637</td>
<td>0.036</td>
<td>-2.30</td>
<td>-2.75</td>
<td>-1.99</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsa-miR-165</td>
<td>0.042</td>
<td>-1.37</td>
<td>-2.14</td>
<td>-2.07</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-654-3p</td>
<td>0.027</td>
<td>-1.29</td>
<td>-1.42</td>
<td>-2.17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-17-3p</td>
<td>0.029</td>
<td>-1.32</td>
<td>-1.21</td>
<td>-2.24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1530</td>
<td>0.017</td>
<td>-1.57</td>
<td>-2.79</td>
<td>-3.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-34b</td>
<td>0.007</td>
<td>-1.13</td>
<td>-3.32</td>
<td>-3.32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-1236</td>
<td>0.000</td>
<td>-4.08</td>
<td>-4.08</td>
<td>-3.98</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Figure B

3' UTR of GALNT3 mRNA

### Figure C

![Graph C](image)

### Figure D

![Graph D](image)